New milestone achieved in SIARC: Automated COVID-19 screening

In January, we have announced the development of SIARC, an automated platform for high-throughput tracking of COVID-19.

Today, SIARC is already being used in Portugal and helping to optimize the laboratory workflow and fast delivery of results. 

The SIARC platform was developed with the intent of filling several identified issues that occurred in between the pipeline of gathering swab samples and providing test results during the COVID-19 pandemic.

Its initial planned development covered the analysis of samples gathered within that method, but rapidly, with the development of new technologies, it was adapted to respond to saliva testing as well.

In this context, SIARC is now a reference in successful technological developments to aid in the fight against the disease.



To allow the intended automation of the diagnosis process, SIARC is divided into several sections and actions, such as:

  • Processes: The homepage of SIARC is the Processes page. It consists of a group of samples, and associated information, which are processed simultaneously. The state of the Process evolves over the course of the laboratory analysis.
  • Quality Control: Whenever samples are unmapped, the program will alert the user. In the quality control section, it will be possible to see what are these samples and review them.
  • Results: The results section shows the results and it will also allow seeing if there are any missing diagnoses.

In addition, SIARC was enriched with a Tests Request section. This section will allow the request for testing from institutions or single individuals.

SIARC is currently in its first version and has already received more than 23 000 samples, from different individuals, institutions, and healthcare facilities. The platform can integrate and export data with vigilance National Health System. The database and registry are a huge gain for active strain vigilance and a narrow follow-up.


Request more information about SIARC by writing to




Comments are closed.